XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
+0.05 (1.10%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.50 - 4.73
52 week 3.42 - 9.57
Open 4.68
Vol / Avg. 2.03M/1.32M
Mkt cap 487.57M
P/E     -
Div/yield     -
EPS -0.84
Shares 107.39M
Beta 2.94
Inst. own 69%
Nov 20, 2014
XOMA Corp at Jefferies Global Healthcare Conference - London
Nov 12, 2014
XOMA Corp at Credit Suisse Healthcare Conference - Webcast
Nov 6, 2014
Q3 2014 XOMA Corp Earnings Call - Webcast
Nov 6, 2014
Q3 2014 XOMA Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -280.35% -349.94%
Operating margin -398.23% -164.18%
EBITD margin - -155.08%
Return on average assets -71.81% -103.18%
Return on average equity - -1419.43%
Employees 180 -
CDP Score - -


United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frederick Kurland Chief Financial Officer, Vice President - Finance, Secretary
Age: 63
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Tom Klein Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Kelvin M. Neu M.D. Director
Age: 41
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 87
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 79
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 61
Bio & Compensation  - Reuters